

Magdy Selim, MD, PhD is a Professor of Neurology at Harvard Medical School and is the Chief of the Stroke Division and Director of the Comprehensive Stroke Center at Beth Israel Deaconess Medical Center in Boston. He has a long track record of dedication to advance stroke care and research. He is well-known for his expertise and research in intracerebral hemorrhage (ICH). He currently leads the “StATin Use in intRacerebral hemorrhage patieNts (SATURN) trial”; the first NINDS-funded trial for secondary prevention of ICH. Dr. Selim also led the efforts to establish the HEmorrhagic stroke Academia inDuStry (HEADS) roundtable; a think-tank group comprised of leading researchers in the field, industry representatives, and decision-makers from regulatory agencies aiming to improve global collaboration in ICH research and to develop a roadmap to expedite the development of new therapies.